• Lepu Biopharma presented Phase III CMG901 results at ESMO 2026, showing improved overall survival in previously treated advanced CLDN18.2-positive gastroesophageal cancer.
• CMG901 did not meet the statistical significance threshold for progression-free survival; its safety profile was manageable.
• AstraZeneca owns CMG901, having licensed global development and commercialization rights in February 2023.
• MRG007 results presented at the meeting showed preliminary antitumor activity in advanced colorectal cancer, supporting ongoing dose optimization with a manageable safety profile.
• Presented Phase II MRG003 findings showed encouraging interim safety in locally advanced head and neck cancer; tumor response data remained preliminary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382753), on October 26, 2026, and is solely responsible for the information contained therein.